Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: Results of a randomized trial

Blood

Volumn 104, Issue 5, 2004, Pages 1559-1564

  Lee, Stephanie J ^a   Zahrieh, David ^b   Agura, Edward ^b   MacMillan, Margaret L ^b   Maziarz, Richard T ^b   McCarthy Jr , Philip L ^b   Ho, Vincent T ^b   Cutler, Corey ^b   Alyea, Edwin P ^b   Antin, Joseph H ^b   Soiffer, Robert J ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DACLIZUMAB; DENILEUKIN DIFTITOX; INFLIXIMAB; INSULIN; INTERLEUKIN 2 RECEPTOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RAPAMYCIN; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; BLADDER DISEASE; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GRAFT VERSUS HOST REACTION; HUMAN; HYPERGLYCEMIA; INFECTION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYOPATHY; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHOOL CHILD; SURVIVAL; T LYMPHOCYTE;

EID: 4444304402     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-03-0854     Document Type: Article

References (32)

1. Gale RP, Bortin MM, van Bekkum DW, et al. Risk factors for acute graft-versus-host disease. Br J Haematol. 1987;67:397-406.
2. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood. 1990;75:1024-1030.
3. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990;76:1464-1472.
4. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962-968.
5. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828.
6. MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant. 2002;8:387-394.
7. Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood. 1998;92:2288-2293.
8. Hings IM, Filipovich AH, Miller WJ, et al. Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment: a prospective randomized trial. Transplantation. 1993;56:577-580.
9. Cahn JY, Bordigoni P, Tiberghien P, et al. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody: a multicenter phase III study. Transplantation. 1995;60:939-942.
10. Martin PJ, Nelson BJ, Appelbaum FR, et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood. 1996;88:824-830.
11. Cragg L, Blazar BR, Defor T, et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2000;6:441-447.
12. Beniaminovitz A, Itescu S, Lietz K, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody [comment]. N Engl J Med. 2000;342:613-619.
13. Bumgardner GL, Hardie I, Johnson RW, et al. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation. 2001;72:839-845.
14. Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ. 2003;326:789.
15. Stratta RJ, Alloway RR, Lo A, Hodge E. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study. Transplantation. 2003;75:1260-1266.
16. Medical Economics Staff. Physician's Desk Reference. Montvale, NJ: Medical Economics Company; 1998.
17. Przepiorka D, Keman NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood. 2000;95:83-89.
18. Anasetti C, Hansen JA, Waldmann TA, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood. 1994;84:1320-1327.
19. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-556.
20. Jennison C, Turnbull BW. The repeated confidence interval approach. J Royal Stat Soc. 1989;51:305-334.
21. Blaise D, Olive D, Michallet M, Marit G, Leblond V, Maraninchi D. Impairment of leukaemia-free survival by addition of interleukin-2- receptor antibody to standard graft-versus-host prophylaxis. Lancet. 1995;345:1144-1146.
22. Belanger C, Esperou-Bourdeau H, Bordigoni P, et al. Use of an anti-interleukin-2 receptor monoclonal antibody for GVHD prophylaxis in unrelated donor BMT. Bone Marrow Transplant. 1993;11:293-297.
23. Anasetti C, Lin A, Nademanee A, et al. A phase II/III randomized, double-blind, placebo-controlled multicenter trial of humanized anti-tac for prevention of acute graft-verus-host disease (GVHD) in recipients of marrow transplants from unrelated donors [abstract]. Blood. 1996;88:621a. Abstract 2472.
24. Weisdorf D, Filipovich A, McGlave P, et al. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation. Bone Marrow Transplant. 1993;12:531-536.
25. Ferrant A, Latinne D, Bazin H, et al. Prophylaxis of graft-versus-host disease in identical sibling donor bone marrow transplant by anti-IL-2 receptor monoclonal antibody LO- Tact-1. Bone Marrow Transplant. 1995;16:577-581.
26. Baan CC, Balk AH, van Riemsdijk JC, et al. Anti-CD25 monoclonal antibody therapy affects the death signals of graft-infiltrating cells after clinical heart transplantation. Transplantation. 2003;75:1704-1710.
27. Lietz K, John R, Beniaminovitz A, et al. Interleukin-2 receptor blockade in cardiac transplantation: influence of HLA-DR locus incompatibility on treatment efficacy. Transplantation. 2003;75:781-787.
28. Nelson DR, Soldevila-Pico C, Reed A, et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl. 2001;7:1064-1070.
29. Bhorade SM, Lurain NS, Jordan A, et al. Emergence of ganciclovir- resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant. 2002;21:1274-1282.
30. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196:389-399.
31. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9:1144-1150.
32. McDyer JF, Li Z, John S, Yu X, Wu CY, Ragheb JA. IL-2 receptor blockade inhibits late, but not early, IFN-gamma and CD40 ligand expression in human T cells: disruption of both IL-12-dependent and -independent pathways of IFN-gamma production. J Immunol. 2002;169:2736-2746.